To investigate the role of the tumor suppressor gene Pdcd4 (programmed cell death 4) in benign and malignant prostate tissue specimen.
INTRODUCTION
Programmed cell death 4 (Pdcd4) is a tumor suppressor gene, which is known to be down-regulated in many tumor entities. It binds to the eukaryotic translation initiation factors eIF4A and eIF4G and inhibits their function by preventing RNA binding (AP-1 transactivation) [1, 2] . The Pdcd4 gene is located on chromosome 10q24 and encodes a 469 aminoacids long protein with two basic domains on the C-and N-terminus and two conserved alpha-helical MA-3 domains. A major regulator of Pdcd4 expression, miR-21 is induced by the TGF-ß pathway. The 3'-UTR region of the Pdcd4 mRNA is a target of the miR-21. High miR-21 concentrations lead to a down-regulation of Pdcd4 and an induction of metastasis, invasion and intravasation in cell culture [3] . In Pdcd4 over-expressing cells, the subsequent carbonic anhydrase II down-regulation shows its influence on the translational level [4] . At the transcriptional level Pdcd4 influences motifs of the promoter of the uPAR gene via phosphorylation of the Sp transcription factors in colorectal cells the Sp1 (specificity protein 1)/Sp3 [5] . Interestingly, this pathway is not confirmed for breast *Address correspondence to this author at the Department of Urology, University of Bonn. Sigmund-Freud-Strasse 25, 53127 Bonn, Germany; Tel: ++49 228 287 14249; Fax: ++49 228 287 19150; E-mail: joerg.ellinger@ukb.uni-bonn.de cancer: the lack of suppression of uPAR transcription by Pdcd4 overexpression therefore shows a possible tissue specific role of Pdcd4 and its involvement in carcinogenesis [6] .
MATERIAL AND METHODOLOGY

Patients
We used tissue microarrays to study the nuclear and cytoplasmic expression pattern of Pdcd4 in malignant and benign prostate tissue. The tissue microarray included 87 prostate tissue samples: prostate cancer n=73, benign prostate tissue n=14; see Table 1 for the detailed clinicopathological information. Tissue samples were derived from patients undergoing radical prostatectomy, respectively from patients with benign prostate hyperplasia undergoing transurethral resection of the prostate at the Department of Urology at the University Hospital Bonn in Germany. The study was approved by the local ethics committee (vote 199/10).
Microarray Construction and Immunohistochemistry
All specimens were fixed in 4% buffered formalin and embedded in paraffin wax. Serial histological sections 4 μm thick were cut from the paraffin blocks and stained with haematoxylin/eosin. The original diagnosis was confirmed in all cases by an independent pathologist. Tumor and benign regions were marked on the slides, and three cores were taken out of the paraffin block and transferred into a recipient block. Pdcd4 immunohistochemical staining was done automatically (DAKO TechMate 500, DAKO, Glostrup, Danmark) according to the manufacturer´s instructions. The anti-Pdcd4 antibody was purchased from Rockland Immunochemicals (Philadelphia, USA) and used at a 1:400 concentration. Negative controls were run concurrently using rabbit igG-isotype. In malignant samples, inflammatory cells, positive stromal cells and normal tissue, all with a high Pdcd4 expression pattern served as an internal control.
Pdcd4 expression was scored by one pathologist who was unaware of the patients' clinical history. As described by Mudduluru et al. nuclear and cytoplasmic immunoreactions were evaluated [7] : Pdcd4 staining quantity was classified in four groups according to the percentage of positively stained nuclei/cytoplasm: score 0, none; score 1, ≤30%; score 2, 30-70%; score 3, ≥70%. In addition, a Pdcd4 intensity score was determined for cytoplasmic and nuclear expression: score 0, none; score 1, weak; score 2, intermediate; score 3, strong. In addition, a total Pdcd4 expression score was calculated as the sum of the nuclear and cytoplasmic scores for intensity and quantity respectively. All cases were divided into four groups: negative/none (score 0), weak/low (score 1 or 2), intermediate/medium (score 3 or 4) and strong staining (score 5 or 6). All images were captured using a pathology scanner (Pannoramic MIDI Scanner, 3DHISTECH, Budapest, Hungary). A representative immunohistochemical staining is shown in Fig. (1A) (benign prostate tissue) and Fig. (1B) (prostate cancer) .
Statistical analysis
Clinicopathological parameters were correlated with Pdcd4 expression using the chi-square-test. Receiver operating characteristics analyses were used to determine the diagnostic information of Pdcd4 expression for the differentiation of prostate cancer and benign prostate tissue. All statistical analyses were done using the Statistical Package for the Social Sciences 20 (IBM Corporation, Somer NY, USA). Significance was concluded at p<0.05.
RESULTS
The nuclear Pdcd4 staining was significantly decreased in prostate cancer tissue (p<0.001, see Table 2 ). Mean   Fig. (1) . Representative staining results of normal (A) and malignant (B) prostate tissue at a magnification of 7x (left image) and 40x (right image).
nuclear and cytoplasmatic staining quantity were 15.6% and 62.6% in prostate cancer tissue compared to 83.6% and 93.3% in benign prostate tissue (see Fig. 2 ): Overall Pdcd4 levels were lower in prostate cancer tissue, however, only Pdcd4 positivity reached significance (p=0.034), whereas the difference concerning the Pdcd4 score did not reach significance (p=0.104). The different nuclear staining pattern allowed to distinguish malignant and benign prostate tissue as determined using receiver operator characteristic analyses: Nuclear quantity reached a specificity of 92.1% and a sensitivity of 14.3% (AUC: 0.783, CI: 0.657-0.908) and nuclear intensity reached a specificity of 81.6% and a sensitivity of 74.4% (AUC: 0.802, CI: 0.676-0.928), whereas Pdcd4 staining reached a specificity of 30.3% and a sensitivity of 92.9% (AUC: 0.616, CI: 0.472-0.759).
We next investigated whether Pdcd4 expression was correlated with adverse clinicopathological parameters. Neither preoperative PSA levels, pathological staging nor Gleason Score were correlated with nuclear or cytoplasmic Pdcd4 expression (all p>0.1), although there was a trend towards lower Pdcd4 levels in locally-advanced and lessdifferentiated prostate cancers. Pdcd4 staining results did not significantly influence cancer specific survival (p=0.132, CI: 48.58-86.35) in our cohort.
DISCUSSION
In this study, we demonstrate that the tumor suppressor gene Pdcd4 is downregulated in prostate cancer tissue. Interestingly, the nuclear and cytoplasmic Pdcd4 expression is different: while nuclear Pdcd4 is steadily downregulated in [7] . The loss of Pdcd4 in most prostate cancer samples and the finding of similar levels in patients with good and adverse prognosis indicates that Pdcd4 expression changes occur early during prostate carcinoge nesis. Göke et al. also demonstrated that Pdcd4 induced the expression of the (CDK)1/cdc2 cyclin-dependent kinase inhibitor p21Waf1/Cip1 [7] . These findings indicate that Pdcd4 acts as tumor suppressor gene. Targeting Pdcd4 could be a future therapeutic option: In a lung cancer mice model, aerosol delivery of a Pdcd4-complex induced apoptosis and inhibited pathways for cell proliferation and tumor angiogenesis [8] .
Earlier studies indicated that Pdcd4 expression is controlled by microRNAs: Davis et al. demonstrated that TGF-beta induced the expression of mature miR-21 in smooth muscle cells; miR-21 in turn suppressed the Pdcd4 levels [9] . A conserved target site for miR-21 is located in the 3'UTR of the Pdcd4 mRNA. Thus, transfection of miR-21 lead to a decrease of Pdcd4. Thereby, miR-21 expression causes invasion, intravasation and metatstasis in a chickenembryo-metastasis assay and in glioblastoma cells [3, 10] . In an earlier study on urothelial carcinoma of the bladder, we found increased miR-21 levels with a suppression of Pdcd4 expression [11] .
Pdcd4 may represent a target for future medical therapy in all prostate cancer patients. Shiota et al. showed that Pdcd4 interacts with the DNA binding domain of the transcription factor Twist1, inhibiting its DNA binding ability and Y-box binding protein-1 (YB-1) expression, and thereby reduces cell growth [12] . Restoration of Pdcd4 expression was associated with an increased sensitivity to cisplatin and paclitaxel chemotherapy in prostate cancer cell lines (PC3) [12] .
CONCLUSION
Our study indicates an important role for Pdcd4 downregulation during prostate carcinogenesis, and Pdcd4 expression differences in normal and malignant tissue may be of diagnostic value, especially when therapeutic aspects of Pdcd4 expression modulation are currently being evaluated. 
